Fremanezumab    (DrugBank: Fremanezumab)

2 diseases
IDDisease name (Link within this page)Number of trials
124Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy1
226Interstitial cystitis with Hunners ulcer1

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy    [ 11 clinical trials,   13 drugs,   (DrugBank: 4 drugs),   3 drug target genes,   11 drug target pathways]
Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 11 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04334408
(ClinicalTrials.gov)
January 20212/4/2020Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILA Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILCadasil;MigraineDrug: Fremanezumab;Drug: PlaceboMayo ClinicNULLNot yet recruiting18 Years70 YearsAll5Phase 2United States

226. Interstitial cystitis with Hunners ulcer    [ 133 clinical trials,   151 drugs,   (DrugBank: 46 drugs),   48 drug target genes,   137 drug target pathways]
Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 133 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04447729
(ClinicalTrials.gov)
October 15, 202010/6/2020A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain SyndromeA Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain SyndromeInterstitial CystitisDrug: fremanezumabTeva Branded Pharmaceutical Products R&D, Inc.NULLWithdrawn18 YearsN/AFemale0Phase 2NULL